NEWSpublisher 2007 :: AngloChinese Investments
SEARCH COMPANY
name:
trunover in millions USD:
from:    to: 
R & D turnover in millions USD:
from:     to: 
NET profit:
from:    to: 
employees:
from:    to: 
COMPANIES
APPROVALS
ACTIVITIES ENGAGED IN
R & D
CLINICAL TRIALS
NON CLINICAL & PRECLINICAL
CHEMISTRY-CONTRACT MANUFACTURE
TEST
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY DETAILS » Novo Nordisk back to previous page show list

Novo Nordisk

»
address: Broadfield Park
Brighton Road
Crawley
West Sussex
RH11 9RT
contact: www.Novonordisk.co.uk

Tel: 01293 613555
Fax: 01293 613535

trunover in millions USD: 6915
R & D turnover in millions USD: 1127
NET profit: 1151
year of financial results: 2006
employees: 23600

active in China: YES
partner in China: Own R & D Facilities in Beijing
Manufacture in Tianjin

& China Academy of Science

SFDA approved: YES
SFDA approved date: 01/06/2003

Approvals:
GLP: YES
GMP: YES
AAALAC: NO
SEPA: NO

Activities engaged in:
Manufacture: YES
Active Pharmaceutical: YES
R&D: YES
Ingredients: YES
Western Generics: NO
TCM: NO

R & D:
Discovery: YES
Work Up (pilot to production): YES
Analysis: YES
Quality Control: YES
Stability: YES
Batch Release: YES

Clinical trials:
Run/Manage: YES
Data management: YES
Support Labs: YES

Non clinical & preclinical:
Animal Testing: GLP: NO
New materials Safety Assessment: NO
Pharmaceuticals: NO
Agrochemicals: NO
Industrial & Other Chemicals: NO
Non GLP - Discovery ADME: NO

Chemistry-contract manufacture:
Generics: NO
API: NO
Licensed Drugs: NO

test:
R&D: YES
 

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy

The Company has R & D facilities in Beijing and manufacturing plant in Tianjin

At the 9th Healthcare Industry Forum in Beijing, Novo Nordisk announced plans to expand its R&D centre in Beijing, China. The expansion will double the number of employees from currently 30 to 60 within the next two-three years.

The expansion is an important step in the internationalization of R&D in Novo Nordisk. The R&D centre in China, which was established in 2002, has already added significantly to Novo Nordisk's expertise in bacterial expression of recombinant proteins and in protein chemistry. Today, the R&D centre in Beijing focuses on three areas: molecular biology, protein chemistry and cell biology.

The R&D unit, situated in Zhongguancun Life Science Park in Beijing, was established in January 2002. It was the first R&D centre established in China by an international biopharmaceutical company with focus on biotech, and also the first R&D unit Novo Nordisk established outside Denmark. The R&D centre in Beijing is an integrated unit of the Biopharmaceuticals Research Unit at Novo Nordisk.


AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.